Heerspink, Z
In SUSTAIN 3, SUSTAIN 7 and SUSTAIN 10, the GLP-1RAs semaglutide reduced HbA1c by up to 1.8%, achieved the glycemic control target of HbA1c in 80% of the intervention group, and reduced BW by up to 6.5 kg, outcomes which were superior to liraglutide, exenatide and dulaglutide [28-30]
At the same time, it provides the body with a stable energy supply, supports the repair of myocardial and other bodily tissues, and enhances the quality of recovery
This science-backed formula combines 10g of prebiotic fiber with clinically shown probiotic strains to support smoother digestion, reduce puff, and ease common digestive discomforts
GLP-1 agonists work best within comprehensive care
Please enable JavaScript and disable any ad blockers or browser extensions that may interfere